Background: Fatigue is common among patients with sarcoidosis. The etiology of this problem is unknown and multifactorial. Fatigue can be confounded with excessive daytime sleepiness (EDS). Fatigue and sleepiness have rarely been studied simultaneously in sarcoidosis patients. Objectives: The aim of this study was the confounder-adjusted estimation of risks for severe fatigue and EDS in a large population of sarcoidosis patients and the development of multivariate predictors from this population. Methods: 1,197 German sarcoidosis patients were examined using the Epworth Sleepiness Scale (ESS), the Fatigue Assessment Scale (FAS), the Hospital Anxiety and Depression Scale (HADS), and the Medical Research Council (MRC) dyspnea scale. Results: 16.5% (123 patients) had EDS (ESS ≥16), 16.4% had severe fatigue (FAS ≥35), and 6.3% had both extreme findings. In a multivariate logistic regression model, predictors of the risk of EDS were a history of sleep apnea (odds ratio [OR] 2.46, 95% confidence interval [CI] 1.5-3.9), dyspnea MRC grade ≥2 (OR 2.29, 95% CI 1.5-3.5), and organ involvement of 4-7 organs (OR 1.60, 95% CI 1.1-2.4). Significantly associated with higher risk of severe fatigue were the following: conspicuous depression (OR 5.95, 95% CI 4.1-8.7), conspicuous anxiety (OR 2.38, 95% CI 1.6-3.4), and muscle pain (OR 1.92, 95% CI 1.32-2.75). The logit models for severe fatigue with and without simultaneous EDS differed only slightly. Conclusion: An extreme form of fatigue and/or sleepiness was found in 27% of all sarcoidosis patients questioned. Because there is a certain overlap, both should be examined simultaneously to allow for a combined assessment.

Journal Section:
Editor's choice
Keywords:
Sarcoidosis, Fatigue, Excessive daytime sleepiness, Dyspnea, Depression, Anxiety, Multivariate predictors
1.
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J: Sarcoidosis. Lancet 2014;383:1155-1167.
2.
Baughman RP, Teirstein AS, Judson MA, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889.
3.
Okumus G, Musellim B, Cetinkaya E, et al: Extrapulmonary involvement in patients with sarcoidosis in Turkey. Respirology 2011;16:446-450.
4.
Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M: Predictors of fatigue in sarcoidosis: the value of exercise testing. Respir Med 2016;116:49-54.
5.
Drent M, Lower EE, De Vries J: Sarcoidosis-associated fatigue. Eur Respir J 2012;40:255-263.
6.
Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J: Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006;130:989-994.
7.
De Kleijn WPE, De Vries J, Lower EE, Elfferich MDP, Baughman RP, Drent M: Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009;15:499-506.
8.
Tavee J, Culver D: Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011;15:201-206.
9.
Drent M, Verbraecken J, van der Grinten C, Wouters E: Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis. Respiration 2000;67:337-340.
10.
Lal C, Medarov BI, Judson MA: Interrelationship between sleep-disordered breathing and sarcoidosis. Chest 2015;148:1105-1114.
11.
Turner GA, Lower EE, Corser BC, Gunther KI, Baughman RP: Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997;14:61-64.
12.
Verbraeken J, Hoitsma E, Van der Grinten CP, Cobben NAM, Wouters EFM, Drent M: Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:137-146.
13.
Patterson KC, Huang F, Oldham JM, Bhardwaj N, Hogarth DK, Mokhlesi B: Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis. Chest 2013;143:1562-1568.
14.
Ohayon MM: From wakefulness to excessive sleepiness: what we know and still need to know. Sleep Med Rev 2008;12:129-141.
15.
Mc Whirter D, Bae C, Budur K: The assessment, diagnosis and treatment of excessive sleepiness: practical considerations for the psychiatrist. Psychiatry 2007;4:26-36.
16.
Beaudreau SA, Spira AP, Stewart A, Kezirian EJ, Lui LY, Ensrud K, Redline S, Ancoli-Israel S, Stone KL: Validation of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale in older black and white women. Sleep Med 2012;13:36-42.
17.
Sander C, Hegerl U, Wirkner K, Walter N, Kocalevent RD, Petrowski K, Glaesmer H, Hinz A: Normative values of the Epworth Sleepiness Scale (ESS), derived from a large German sample. Sleep Breath 2016;20:1337-1345.
18.
Dixon JB, Dixon ME, Anderson ML, Schachter L, O'Brien PE: Daytime sleepiness in the obese: not as simple as obstructive sleep apnea. Obesity 2007;15:2504-2511.
19.
Taylor-Gjevre RM, Gjevre JA, Nair B, Skomro R, Lim HJ: Hypersomnolence and sleep disorders in a rheumatic disease patient population. J Clin Rheumatol 2010;16:255-261.
20.
Costa Faria A, da Costa CH, Rufino R: Sleep Apnea Clinical Score, Berlin Questionnaire, or Epworth Sleepiness Scale: which is the best obstructive sleep apnea predictor in patients with COPD? Int J Gen Med 2015;8:275-281.
21.
Hinz A, Fleischer M, Brähler E, Wirtz H, Bosse-Henck A: Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011;33:462-468.
22.
Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
23.
De Vries J, Michielsen H, Van Heck GI, Drent M: Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004;9:279-291.
24.
Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
25.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-586.
26.
Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM: Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003;26:1049-1054.
27.
Hawley CJ, Gale TM, Sivakumaran T, Paul S, Kondan VR, Farag A, Shahzad J: Excessive daytime sleepiness in psychiatric disorders: prevalence, correlates and clinical significance. Psychiatry Res 2010;175:138-141.
28.
De Kleijn PE, Drent M, Vermunt JK, Shigemitsu H, De Vries J: Types of fatigue in sarcoidosis patients. J Psychosom Res 2011;71:416-422.
29.
Baughman RP, Judson MA: Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J 2014;43:337-339.
30.
Marcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, Lenssen A: Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis 2015;32:53-62.
31.
Cavalcante AGM, de Bruin PFC, de Bruin VMS, Pereira EDB, Cavalcante MM, Nunes DM: Restless legs syndrome, sleep impairment, and fatigue in chronic obstructive pulmonary disease. Sleep Med 2012;13:842-847.
32.
Gvozdenovic BC, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA: Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008;102:1636-1642.
33.
Lill H, Kliiman K, Altraja A: Factors signifying gender differences in clinical presentation of sarcoidosis among Estonian population. Clin Respir J 2016;10:282-290.
34.
Myers KA, Mrkobrada M, Simel DL: Does this patient have obstructive sleep apnea? The Rational Clinical Examination systematic review. JAMA 2013;310:731-741.
35.
Bailes S, Libman E, Baltzan M, Grad R, Kassissia I, Creti L, Rizzo D, Amsel R, Fichten CS: Fatigue: the forgotten symptom of sleep apnea. J Psychosom Res 2011;70:346-354.
36.
De Kleijn WPE, Drent M, De Vries J: Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Brit J Health Psychol 2013;18:439-452.
37.
Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M: Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005;60:32-38.
38.
Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H: Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration 2016;91:497-502.
39.
Córdoba-Torrecilla S, Aparicio VA, Soriano-Maldonado A, Estévez-López F, Segura-Jiménez V, Álvarez-Gallardo I, Femia P, Delgado-Fernandez M: Physical fitness is associated with anxiety levels in women with fibromyalgia: the Al-Ándalus Project. Qual Life Res 2016;25:1053-1058.
40.
Segura-Jiménez V, Soriano-Maldonado A, Estévez-López F, Álvarez-Gallardo I, Delgado-Fernandez M, Ruiz JR, Aparicio VA: Independent and joint associations of physical activity and fitness with fibromyalgia symptoms and severity: the Al-Ándalus Project. J Sports Sci 2016;35:1565-1574.
41.
Theorell-Haglöw J, Åkerstedt T, Schwarz J, Lindberg E: Predictors for development of excessive daytime sleepiness in women: a population-based 10-year follow-up. Sleep 2015;38:1995-2003.
42.
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Skler 2009;15:385-392.
43.
Somaini G, Hasler ED, Saxer S, Huber LC, Lichtblau M, Speich R, Bloch KE, Ulrich S: Prevalence of anxiety and depression in pulmonary hypertension and changes during therapy. Respiration 2016;91:359-366.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.